<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rallybio Corp — News on 6ix</title>
<link>https://6ix.com/company/rallybio-corp</link>
<description>Latest news and press releases for Rallybio Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 02 Mar 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rallybio-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b8cd78dffbe2df115264.webp</url>
<title>Rallybio Corp</title>
<link>https://6ix.com/company/rallybio-corp</link>
</image>
<item>
<title>Rallybio Corporation and Candid Therapeutics Announce Merger Agreement</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-corporation-and-candid-therapeutics-announce-merger-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-corporation-and-candid-therapeutics-announce-merger-agreement</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent</description>
</item>
<item>
<title>Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-announces-positive-data-for-rlyb116-phase-1-study-demonstrating-complete-and-sustained-inhibition-of-terminal-complement</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-announces-positive-data-for-rlyb116-phase-1-study-demonstrating-complete-and-sustained-inhibition-of-terminal-complement</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., February 17, 2026--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor, in development for patients with complement-mediate</description>
</item>
<item>
<title>Rallybio Announces Reverse Stock Split of Common Stock</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-announces-reverse-stock-split-210500160</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-announces-reverse-stock-split-210500160</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>NEW HAVEN, Conn., February 03, 2026--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restated Certificate of Incorporation (the "Amendment") to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for futu</description>
</item>
<item>
<title>Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-reports-third-quarter-2025-130000143</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-reports-third-quarter-2025-130000143</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., November 06, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments.</description>
</item>
<item>
<title>Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-completes-dosing-first-cohort-120000129</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-completes-dosing-first-cohort-120000129</guid>
<pubDate>Thu, 25 Sep 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., September 25, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.</description>
</item>
<item>
<title>Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-receives-12-5-million-120000322</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-receives-12-5-million-120000322</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., September 03, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it received an equity milestone payment of $12.5 million from Recursion. The milestone payment was triggered by the initiation of additional preclinical studies for REV102, an investigational ENPP1 inhibitor in development for the treatment of hypophosphatas</description>
</item>
<item>
<title>Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-reports-second-quarter-2025-120000338</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-reports-second-quarter-2025-120000338</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., August 07, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments.</description>
</item>
<item>
<title>Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-sells-interest-rev102-program-120000058</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-sells-interest-rev102-program-120000058</guid>
<pubDate>Tue, 08 Jul 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., July 08, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals for up to $25 million, including</description>
</item>
<item>
<title>ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors</title>
<link>https://6ix.com/company/rallybio-corp/news/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/immunoprecise-antibodies-appoints-industry-veteran-jon-lieber-to-board-of-directors</guid>
<pubDate>Mon, 07 Jul 2025 13:00:00 GMT</pubDate>
<description>AUSTIN, Texas, July 07, 2025--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.</description>
</item>
<item>
<title>Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-initiates-dosing-rlyb116-phase-120000675</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-initiates-dosing-rlyb116-phase-120000675</guid>
<pubDate>Thu, 12 Jun 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., June 12, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.</description>
</item>
<item>
<title>Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-reports-first-quarter-2025-120000377</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-reports-first-quarter-2025-120000377</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., May 08, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments.</description>
</item>
<item>
<title>Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-present-2025-citizens-jmp-120000606</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-present-2025-citizens-jmp-120000606</guid>
<pubDate>Tue, 29 Apr 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., April 29, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY.</description>
</item>
<item>
<title>Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-discontinue-development-rlyb212-prevention-120000948</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-discontinue-development-rlyb212-prevention-120000948</guid>
<pubDate>Tue, 08 Apr 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., April 08, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company’s decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the</description>
</item>
<item>
<title>Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-reports-fourth-quarter-full-120000145</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-reports-fourth-quarter-full-120000145</guid>
<pubDate>Thu, 13 Mar 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., March 13, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on recent company developments.</description>
</item>
<item>
<title>Rallybio to Present at the TD Cowen 45th Annual Health Care Conference</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-present-td-cowen-45th-130000917</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-present-td-cowen-45th-130000917</guid>
<pubDate>Tue, 25 Feb 2025 13:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., February 25, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will present a corporate overview at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 1:10 p.m. EST in Boston, MA.</description>
</item>
<item>
<title>Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-announces-initiation-of-dosing-in-rlyb212-phase-2-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-announces-initiation-of-dosing-in-rlyb212-phase-2-clinical-trial</guid>
<pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
<description>– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a</description>
</item>
<item>
<title>Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-highlights-2024-accomplishments-and-anticipated-milestones-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-highlights-2024-accomplishments-and-anticipated-milestones-for-2025</guid>
<pubDate>Fri, 10 Jan 2025 05:00:00 GMT</pubDate>
<description>– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study Expected in</description>
</item>
<item>
<title>Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-announces-promising-rlyb212-and-rlyb332-preclinical-data-at-the-66th-american-society-of-hematology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-announces-promising-rlyb212-and-rlyb332-preclinical-data-at-the-66th-american-society-of-hematology-annual-meeting</guid>
<pubDate>Tue, 10 Dec 2024 05:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into</description>
</item>
<item>
<title>Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-to-initiate-rlyb116-confirmatory-clinical-pkpd-study-in-second-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-to-initiate-rlyb116-confirmatory-clinical-pkpd-study-in-second-quarter-2025</guid>
<pubDate>Mon, 02 Dec 2024 05:00:00 GMT</pubDate>
<description>-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study – --</description>
</item>
<item>
<title>Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women</title>
<link>https://6ix.com/company/rallybio-corp/news/rallybio-announces-publication-of-target-mediated-drug-disposition-modeling-and-simulations-informing-the-rlyb212-dosing-regimen-in-pregnant-women</link>
<guid isPermaLink="true">https://6ix.com/company/rallybio-corp/news/rallybio-announces-publication-of-target-mediated-drug-disposition-modeling-and-simulations-informing-the-rlyb212-dosing-regimen-in-pregnant-women</guid>
<pubDate>Wed, 27 Nov 2024 05:00:00 GMT</pubDate>
<description>— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq:</description>
</item>
</channel>
</rss>